Keywords: Denosumab, Zoledronic acid, Breast cancer, Bone metastases, Amgen, Prolia, Xgeva, Novartis, Reclast

Denosumab superior to zoledronic acid for breast cancer patients with bone metastases

Article | 15 August 2012

Print This

Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in